Trial Profile
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Keratoconjunctivitis Sicca
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Piclidenoson (Primary)
- Indications Keratoconjunctivitis sicca
- Focus Therapeutic Use
- Sponsors Can-Fite BioPharma
- 24 Sep 2014 New trial record